Charles River and PathoQuest Strengthen Strategic Partnership
November 12 2020 - 8:00AM
Business Wire
PathoQuest establishes U.S. subsidiary with
state-of-the-art biologics genomic testing laboratory in Wayne, PA
to expand its next-generation sequencing capabilities
PathoQuest SAS, a genomic expert company dedicated to quality
control testing of biologics, and its strategic partner Charles
River Laboratories International, Inc. (NYSE: CRL), announced today
that it has established a U.S. subsidiary, PathoQuest, Inc., and
will construct a state-of-the-art next generation sequencing
(NGS)-based testing laboratory at Charles River’s site in Wayne,
PA. The establishment of this lab will enhance the strategic
partnership between the two companies and will also expand Charles
River’s and PathoQuest's capabilities to meet client needs by
providing a fully integrated and reliable solution for rapid viral
safety testing of biologics, notably advanced therapeutic medicinal
products (ATMPs) and vaccines.
The expanded relationship between PathoQuest and Charles River
will offer North American biotechnology companies a NGS testing
facility in the U.S. that identifies adventitious agents using
PathoQuest’s rapid, in vitro, comprehensive testing approach which
accelerates development timelines of biologics without compromising
safety and efficacy. This NGS approach can also be utilized for the
genetic characterization of cell lines. The partnership between
Charles River and PathoQuest provides clients with the most
sensitive and rapid testing methodologies to help ensure the safety
of products produced by the biopharmaceutical industry.
Construction of PathoQuest’s new office and laboratory facility
is scheduled to begin in late 2020 with NGS services expected to be
available in 2021. Once complete, the lab will be aligned with
PathoQuest’s existing lab in Paris and offer testing that adheres
to Current Good Manufacturing Practices (CGMP) in accordance with
U.S. Food and Drug Administration guidelines. This solution will
offer the biopharmaceutical industry a comprehensive offering of
testing services performed within the same facility, enabling rapid
and reliable support for biologics development and quality control
testing.
Charles River’s Wayne facility supports the development of
biological products, including cell line characterization, viral
safety, and viral clearance studies. Charles River has made an
additional direct investment in PathoQuest to help fund the
establishment of this new facility and to support the expansion of
PathoQuest’s testing platform into North America.
Approved Quotes
- “The addition of a PathoQuest facility at the Wayne site
highlights our commitment to addressing our clients’ dynamic needs.
PathoQuest’s NGS-based testing solution provides a rapid, reliable
and comprehensive testing solution, and now, clients will have it
at their fingertips through this expanded partnership.” – Birgit
Girshick, Corporate Executive Vice President, Discovery and Safety
Assessment, Biologics Testing Solutions, and Avian Vaccine
Services, Charles River
- “Our NGS-based approach provides a state-of-the-art quality
control testing solution for biopharmaceutical quality assurance
and production managers. Our new facility in Wayne will create
additional opportunities to integrate with Charles River’s service
offerings and expose more pharmaceutical and biotechnology groups
to our technology, furthering the rapid expansion of our business.”
– Jean-Francois Brepson, President and CEO, PathoQuest
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
About PathoQuest
PathoQuest as pharmaceutical establishment offers
biopharmaceutical companies a game changing Genomic QC testing to
secure the biosafety of biological drugs like cell & gene
therapy products, vaccines and recombinant. It enables the ability
to reduce the turnaround time for safety testing, replacing
traditional methods like animal testing. PathoQuest’s technology
combines a Next-Generation Sequencing (NGS) platform with a
proprietary sample preparation process completed by proprietary
pathogen genome sequence databases and automated analysis
pipeline.
Based on its technological platform, PathoQuest has also
developed a metagenomic test direct from blood (iDTECT®) to improve
the diagnosis of Bloodstream infections and fight against
Antimicrobial Resistance (AMR). For more information about
PathoQuest, visit www.pathoquest.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201112005153/en/
Investor Contact for PathoQuest: Patrick COURT CFO
finance@pathoquest.com Media Contact for PathoQuest: Ophélie
PHILIPOT External Communications Manager
ophelie.philipot@comopi.tech Investor Contact for Charles
River: Todd Spencer Corporate Vice President, Investor
Relations 781-222-6455 todd.spencer@crl.com Media Contact for
Charles River: Amy Cianciaruso Corporate Vice President, Public
Relations 781-222-6168 amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Apr 2023 to Apr 2024